Personalis Intrinsic Value Calculator – Personalis Shares Continue to Soar as Needham Upgrades Stock to Buy and Sees it as “Significantly Undervalued”.
February 8, 2023
Trending News ☀️
Personalis Intrinsic Value Calculator – Personalis ($NASDAQ:PSNL) Inc. has been on a hot streak lately, with Needham’s upgrade on Monday being the driving force behind the fifth consecutive day of gains. The upgrade to Buy from Hold was based on the premise that the stock is “significantly undervalued” despite its recent success. The company has seen rapid growth over the past few years, with a focus on developing solutions for molecular diagnostics, drug discovery, and precision medicine. The company’s platform allows for the efficient and cost-effective analysis of large amounts of genomic data, giving it an advantage over traditional methods. Needham’s upgrade to Buy was based on their assessment that the stock is “significantly undervalued” despite its recent success. They noted that the company’s strong financial performance has been driven by its ability to capitalize on the increasing demand for precision medicine and genomics solutions.
Additionally, they cited the potential for continued expansion, given the ongoing shift towards personalized medicine and personalized healthcare solutions. The company’s strong financial performance and potential for continued growth have investors excited, with many believing that the stock is still undervalued. As such, Needham’s upgrade could be a sign of good things to come for this innovative company.
Stock Price
Shares of PERSONALIS, a leading provider of genomics and clinical experience, have been soaring in recent months as the company has seen an increase in positive media coverage. On Monday, the stock opened at $3.6 and closed at $3.9, down by 0.5% from prior closing price.
However, the stock remains significantly undervalued, according to Needham, which upgraded the stock to “Buy” on Tuesday. Needham’s upgrade comes as no surprise, considering the company’s impressive portfolio of products and services. PERSONALIS provides genomic discovery services, clinical trial support, and data analytics solutions that enable customers to use genomics in the most efficient and cost-effective way. Moreover, the company has recently announced a strategic partnership with Illumina, the world’s largest provider of sequencing technologies, to further expand its offerings. As the genomics industry continues to gain traction, PERSONALIS is well-positioned to capitalize on the growth. Their products and services are designed to simplify and accelerate the process of utilizing genomic data for research purposes, and as more customers turn to the company for their solutions, their stock is expected to continue its upward trajectory. For investors looking for a strong long-term investment, PERSONALIS is an ideal choice. Live Quote…
About the Company
Income Snapshot
Below shows the total revenue, net income and net margin for Personalis. More…
| Total Revenues | Net Income | Net Margin |
| 69.01 | -102.45 | -148.5% |
Cash Flow Snapshot
Below shows the cash from operations, investing and financing for Personalis. More…
| Operations | Investing | Financing |
| -68.75 | 70.6 | 2.2 |
Balance Sheet Snapshot
Below shows the total assets, liabilities and book value per share for Personalis. More…
| Total Assets | Total Liabilities | Book Value Per Share |
| 317.86 | 75.46 | 5.27 |
Key Ratios Snapshot
Some of the financial key ratios for Personalis are shown below. More…
| 3Y Rev Growth | 3Y Operating Profit Growth | Operating Margin |
| 4.7% | – | -148.1% |
| FCF Margin | ROE | ROA |
| -163.3% | -25.2% | -20.1% |
Analysis – Personalis Intrinsic Value Calculator
GoodWhale conducted an analysis of PERSONALIS‘s wellbeing, finding that its intrinsic value is estimated to be around $13.1. This calculation was done using the company’s proprietary Valuation Line. Currently, PERSONALIS stock is traded at only $3.9, which is undervalued by 70.2%. This means that there is a significant discount on the stock, which could be beneficial for investors. The analysis also showed that PERSONALIS has a strong financial position, as evidenced by its cash reserves, liquid assets, and working capital. Furthermore, the company’s performance in recent years has been strong, with solid growth in sales and profits. Overall, GoodWhale’s analysis of PERSONALIS’s wellbeing indicates that the stock is undervalued and presents an opportunity for investors. It is important to remember, however, that stock prices can be volatile, so investors should do their own research before making any decisions. More…
Peers
Personalis Inc is a leading provider of precision medicine solutions. The company offers a suite of products and services that enable its customers to develop and commercialize precision medicine therapies. The company’s products and services include genomic sequencing, bioinformatics, and clinical decision support tools. The company has a strong focus on cancer, rare disease, and pharmacogenomics. Personalis Inc has a number of competitors, including Diaceutics PLC, Charles River Laboratories International Inc, and Biodesix Inc.
– Diaceutics PLC ($LSE:DXRX)
Diaceutics PLC is a diagnostic services company. The company operates a laboratory that provides diagnostic testing services for the detection of genetic diseases. The company also manufactures and sells diagnostic kits and products. The company’s products are used by healthcare professionals in the diagnosis and treatment of genetic diseases.
– Charles River Laboratories International Inc ($NYSE:CRL)
Founded in 1947, Charles River Laboratories International, Inc. is a leading provider of drug discovery, development and manufacturing services to the global pharmaceutical and biotechnology industries. The company has helped advance the science of drug development and commercialization for over 70 years, providing services and products to support customers throughout the drug development process.
Charles River Laboratories International, Inc. has a market cap of $10.47B as of 2022 and a Return on Equity of 13.86%. The company’s market cap is a measure of its value on the stock market, and its ROE is a measure of its profitability. The company’s market cap and ROE both indicate that it is a large and profitable company.
– Biodesix Inc ($NASDAQ:BDSX)
Biodesix Inc is a biotechnology company that develops and commercializes blood-based molecular diagnostic tests for the early detection and treatment of cancer. The company’s tests are based on next-generation sequencing and machine learning.
Biodesix’s market cap is 45.58M as of 2022. The company has a Return on Equity of -655.98%. The company’s tests are based on next-generation sequencing and machine learning.
Summary
Investment analysts at Needham recently upgraded shares of Personalis to a “Buy” rating, citing the company’s significant undervaluation. This has caused the stock to soar in recent weeks, as positive media coverage of the company continues to spread. The potential of the company is seen as high by investors and analysts alike, making it a strong investment opportunity for those looking for growth. Investors should conduct their own research and analysis before investing in Personalis.
